Market Overview

Shares of Intercept Pharma Rise as BofA Sees US, EU Regulators Giving A Thumbs Up

Related ICPT
Intercept Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology
The Top 25 Analysts On Wall Street
Making Money With Charles Payne: 12/22/14 (Fox Business)

On Monday, Bank of America released a bullish note on Intercept Pharmaceuticals (NASDAQ: ICPT). Shares trended higher throughout the session, spiking over the $440 level just minutes before the bell. The stock closed up nearly 8 percent.

Analyst Rachel McMinn believes the company should see FDA and EU regulators' support on using reversal of steatohepatitis, with no fibrosis progression, as surrogate histologic endpoint. Intercept's endpoint is to approve non-alcoholic steatohepatitis (NASH) drugs for the pre-cirrhotic population, according to the BofA analyst.

McMinn believes that regulators will need Phase 3 studies for approval, but regulators won't require CV outcomes data prior to approval.

Latest Ratings for ICPT

DateFirmActionFromTo
Dec 2014CitigroupMaintainsBuy
Dec 2014Bank of AmericaReinstatesBuy
Dec 2014FBR CapitalMaintainsUnderperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (ICPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters